TapewireFind a company

person · Reporting owner

Mahoney Stephen F.

Disclosed activity across 3 companies

Tapewire entity
61971
SEC CIK
0001741389

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813See RemarksNovember 30, 2022December 02, 2022
Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954President & COOSeptember 17, 2019September 19, 2019
Viridian Therapeutics, Inc.\DEVRDN · Entity 4316Director · President and CEOMarch 03, 2026March 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dianthus Therapeutics, Inc. /DE/

Report date November 30, 2022 · Filed December 02, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect17,264 Reported balance After 2022-11-30 transaction · row 1
1 source row

Row 1 · 2022-11-30 · Grant · Acquired 3,000 · Balance 17,264

F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022.

Kiniksa Pharmaceuticals International, plc

Report date September 17, 2019 · Filed September 19, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.83 · Expires 2029-09-16Direct82,000 Reported balance After 2019-09-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-09-17 · Grant · Acquired 82,000 · Balance 82,000

F1: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.

Viridian Therapeutics, Inc.\DE

Report date March 03, 2026 · Filed March 09, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect33,349 Reported balance After 2026-03-03 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2026-03-03 · Tax withholding · Disposed 7,408 · Balance 33,349

F1: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 03, 2026 Filed Mar 4, 2026 23:56 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionRestricted Stock Units · Derivative 18,357 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-092036 · ownership.xml · derivative · entry 5

Mahoney Stephen F. · CIK 0001741389 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,071

Underlying: Common Stock · 18,357 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
March 03, 2026 Filed Mar 4, 2026 23:56 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Tax withholdingCommon Stock 7,627 $29.32 $223,623.64
Disclosure

SEC source: 0001193125-26-092036 · ownership.xml · nonDerivative · entry 2

Mahoney Stephen F. · CIK 0001741389 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,130

F5 · balance_after: Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

Read SEC document
March 03, 2026 Filed Mar 4, 2026 23:56 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 18,357 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-092036 · ownership.xml · nonDerivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,757

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F5 · balance_after: Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

Read SEC document
March 03, 2026 Filed Mar 9, 2026 23:35 UTC Amendment Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Tax withholdingCommon Stock 7,408 $30.19 $223,647.52
Disclosure

SEC source: 0001193125-26-099007 · ownership.xml · nonDerivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,349

F1 · shares: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

F1 · balance_after: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 23:56 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 GrantRestricted Stock Units · Derivative 111,900 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-092036 · ownership.xml · derivative · entry 4

Mahoney Stephen F. · CIK 0001741389 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,900

Underlying: Common Stock · 111,900 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 23:56 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 GrantStock Option (Right to Buy) · Derivative 559,600 $0.00 Strike: $30.25 $0.00
Disclosure

SEC source: 0001193125-26-092036 · ownership.xml · derivative · entry 3

Mahoney Stephen F. · CIK 0001741389 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 559,600

Underlying: Common Stock · 559,600 shares

Expires 2036-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 02:14 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 GrantRestricted Stock Units · Derivative 73,428 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-032891 · ownership.xml · derivative · entry 2

Mahoney Stephen F. · CIK 0001741389 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,428

Underlying: Common Stock · 73,428 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 02:14 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 GrantStock Option (Right to Buy) · Derivative 440,565 $0.00 Strike: $14.41 $0.00
Disclosure

SEC source: 0000950170-25-032891 · ownership.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 440,565

Underlying: Common Stock · 440,565 shares

Expires 2035-03-03

F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 3, 2025.

Read SEC document
September 27, 2024 Filed Sep 30, 2024 23:10 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 PurchaseCommon Stock 21,400 $23.33 $499,262.00
Disclosure

SEC source: 0000950170-24-110484 · ownership.xml · nonDerivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,400

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:35 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 GrantStock Option (Right to Buy) · Derivative 1,259,400 $0.00 Strike: $13.02 $0.00
Disclosure

SEC source: 0000950170-23-057519 · ownership.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,259,400

Underlying: Common Stock · 1,259,400 shares

Expires 2033-10-30

F1 · derivative.exercise_date: The option vests as to 25% on October 30, 2024 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
November 30, 2022 Filed Dec 2, 2022 21:23 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantCommon Stock 3,000 $0.94 $2,820.00
Disclosure

SEC source: 0000899243-22-037433 · doc4.xml · nonDerivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,264

F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022.

Read SEC document
August 01, 2022 Filed Aug 2, 2022 01:11 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 130,000 $0.00 Strike: $1.57 $0.00
Disclosure

SEC source: 0000899243-22-027266 · doc4.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2032-07-31

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022.

Read SEC document
May 17, 2022 Filed May 19, 2022 20:19 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 62,500 $0.00 Strike: $1.18 $0.00
Disclosure

SEC source: 0000899243-22-018804 · doc4.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2032-05-16

F1 · derivative.exercise_date: This option shall vest and become exercisable in three equal installments, each installment vesting every six months, over the 18 months following the vesting commencement date. The vesting commencement date is May 15, 2022.

Read SEC document
February 15, 2022 Filed Feb 17, 2022 22:16 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 130,000 $0.00 Strike: $3.19 $0.00
Disclosure

SEC source: 0000899243-22-006814 · doc4.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2032-02-14

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022.

Read SEC document
September 16, 2021 Filed Sep 20, 2021 21:02 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 5,736 $6.73 $38,603.28
Disclosure

SEC source: 0000899243-21-036601 · doc4.xml · nonDerivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,264

F1 · kind: This transaction represents shares sold solely to pay taxes due upon the vesting of restricted stock units, as disclosed by the reporting person on the Form 4 filed on September 16, 2021.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.87, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 14, 2021 Filed Sep 16, 2021 23:41 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-036337 · doc4.xml · nonDerivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: On February 11, 2021, the reporting person was granted 40,000 restricted stock units. The restricted stock units vest in two equal installments subject to the achievement of certain performance milestones related to the issuer's business plans. The first performance milestone was achieved, resulting in vesting of 20,000 restricted stock units and the corresponding issuance of 20,000 shares of issuer common stock.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 21:39 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 435,000 $0.00 Strike: $6.28 $0.00
Disclosure

SEC source: 0000899243-20-030392 · doc4.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,000

Underlying: Common Stock · 435,000 shares

Expires 2030-11-01

F1 · derivative.exercise_date: This option shall vest and become exerciseable over four years, with 25% of this option vesting on November 2, 2021, and the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document
September 17, 2019 Filed Sep 19, 2019 20:18 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantShare Option · Derivative 82,000 $0.00 Strike: $8.83 $0.00
Disclosure

SEC source: 0001179110-19-010490 · edgar.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,000

Underlying: Class A Common Shares · 82,000 shares

Expires 2029-09-16

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.

Read SEC document
March 04, 2019 Filed Mar 6, 2019 23:30 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantShare Option · Derivative 83,000 $0.00 Strike: $17.92 $0.00
Disclosure

SEC source: 0001104659-19-013176 · a4.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,000

Underlying: Class A Common Shares · 83,000 shares

Expires 2029-03-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.

Read SEC document
September 20, 2018 Filed Sep 24, 2018 12:58 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantShare Option · Derivative 50,000 $0.00 Strike: $30.93 $0.00
Disclosure

SEC source: 0001104659-18-058109 · a4.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Class A Common Shares · 50,000 shares

Expires 2028-09-19

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is September 20, 2018.

Read SEC document
May 29, 2018 Filed May 29, 2018 23:18 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 ConversionClass B Common Shares · Derivative 107,050 $0.00 $0.00
Disclosure

SEC source: 0001104659-18-036484 · a4.xml · derivative · entry 6

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 656,027

Underlying: Class A Common Shares · 107,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Class B Common Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F4 · derivative.exercise_date: Each share of Class B Common Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F4 · derivative.expiration_date: Each share of Class B Common Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

Read SEC document
May 29, 2018 Filed May 29, 2018 23:18 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 ConversionSeries C Preferred Shares · Derivative 6,392 $0.00 $0.00
Disclosure

SEC source: 0001104659-18-036484 · a4.xml · derivative · entry 5

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 6,392 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

Read SEC document
May 29, 2018 Filed May 29, 2018 23:18 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 ConversionSeries A Preferred Shares · Derivative 107,050 $0.00 $0.00
Disclosure

SEC source: 0001104659-18-036484 · a4.xml · derivative · entry 4

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class B Common Shares · 107,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.

F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.

F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.

Read SEC document
May 29, 2018 Filed May 29, 2018 23:18 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 ConversionClass A Common Shares 6,392 $0.00 $0.00
Disclosure

SEC source: 0001104659-18-036484 · a4.xml · nonDerivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 09, 2018 Filed May 29, 2018 23:18 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 PurchaseSeries C Preferred Shares · Derivative 6,392 $15.64 $99,995.17
Disclosure

SEC source: 0001104659-18-036484 · a4.xml · derivative · entry 3

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,392

Underlying: Class A Common Shares · 6,392 shares

Expires not disclosed

F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F2 · shares: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018.

F2 · price: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018.

F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F2 · derivative.underlying_shares: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018.

F2 · balance_after: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.